Cargando…

Discussion session: biomarker trials

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Invited Speaker Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658685/ http://dx.doi.org/10.1186/1745-6215-16-S2-I2

Ejemplares similares

Using biomarkers prospectively in adaptive clinical trials
por: Berry, Donald A
Publicado: (2011)

New tools to diagnose and follow FAC patients: biomarkers
por: Merlini, Giampaolo
Publicado: (2015)

S48. Biomarker development for ipilimumab and prostate GVAX treatment
por: de Gruijl, T, et al.
Publicado: (2014)

Is lack of habituation a biomarker of migraine? A critical perspective
por: Brighina, Filippo, et al.
Publicado: (2015)

Controversies about the role of the deficit of habituation of evoked potentials in migraine: a disease biomarker? PROS
por: Ambrosini, Anna
Publicado: (2015)

S49. Clinical activity and development of biomarkers for an engineered anti PDL1 antibody MPDL3280A
por: Cha, E
Publicado: (2014)

The madness of HIV prevention trials
por: McCormack, S
Publicado: (2015)

Equivalence and non inferiority trials
por: D’Agostino, Ralph B
Publicado: (2011)

EDI200 therapeutic trial
por: Huttner, Kenneth
Publicado: (2012)

Investigator led trials: challenges and opportunities
por: Sandercock, Peter
Publicado: (2011)

Seven myths of randomisation in clinical trials
por: Senn, Stephen
Publicado: (2011)

Randomised controlled trials of complex interventions
por: Norrie, John
Publicado: (2011)

Removing unnecessary obstacles to randomised trials
por: Collins, Rory
Publicado: (2013)

Strategies for handling missing data in randomised trials
por: White, Ian R
Publicado: (2011)

Identifying appropriate phase II trial designs
por: Brown, Sarah R
Publicado: (2011)

Trials in rare diseases: the need to think differently
por: Billingham, Lucinda, et al.
Publicado: (2011)

Science in a crisis: conducting clinical trials in an emergency
por: Horby, P
Publicado: (2015)

Survival analysis: coping with non proportional hazards in randomized trials
por: Royston, Patrick, et al.
Publicado: (2011)

The UK Medical Research Council and clinical trials, 1934-1960
por: Chalmers, Iain
Publicado: (2013)

Science, society and biosafety of a field trial with transgenic biofuel poplars
por: Van Acker, Rebecca, et al.
Publicado: (2011)

When to decide to enroll a TTR-FAP patient in a Clinical Trial?
por: Buades, Juan
Publicado: (2015)

Recruitment to trials - why is it hard and how might we make it less so?
por: Treweek, Shaun
Publicado: (2011)

INSP-04. Confirmatory adaptive designs for survival trials with several time-to-event endpoints
por: Schmidt, Rene
Publicado: (2022)

Streamlining regulation of clinical trials – update on the Academy of Medical Sciences review and government’s response
por: Ford, Gary A
Publicado: (2011)

Using economic modelling to contribute to the prioritisation and design and clinical trials: ready for prime time
por: Sculpher, Mark
Publicado: (2011)

Statistical issues in the analysis of non-pharmacological therapy trials with clustering by care-provider or therapy group
por: Roberts, Chris
Publicado: (2011)

S5. Proffered paper: Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703: clinical and immunological predictive pretreatment factors of activity in the IMPACT trial
por: Schmoll, H, et al.
Publicado: (2014)

INSP-06. Recent advances in improving neuropsychological outcomes for paediatric brain tumour patients - Are we entering a new era?
por: Mabbott, Donald
Publicado: (2022)

INSP-09. Using genetically engineered mouse models and patient-derived orthotopic xenografts to develop new therapies for pediatric brain tumors.
por: Jonchere, Barbara, et al.
Publicado: (2022)

INSP-08. Cerebellar mutism syndrome: incidence, symptoms, risk factors, prognosis. Results and future perspectives from the Nordic-European study of the cerebellar mutism syndrome
por: Sehested, Astrid, et al.
Publicado: (2022)

INSP-03. Neuronal regulation of glioma progression
por: Monje, Michelle
Publicado: (2022)

INSP-17. Augmented Drug Delivery for Pediatric Diffuse Midline Glioma using Convection Enhanced Delivery
por: Souweidane, Mark M
Publicado: (2022)

INSP-14. Novel approaches to molecular diagnostics
por: Sahm, Felix
Publicado: (2022)

INSP-07. Improving cognitive outcomes for children treated for cancer: moving beyond the cure
por: Conklin, Heather
Publicado: (2022)

INSP-01. What to do when you cannot randomize? Leveraging Historical Data in Efficient Study Designs for Pediatric Neuro-Oncology.
por: Onar-Thomas, Arzu
Publicado: (2022)

INSP-02. WHO 2021 classification of CNS tumors
por: Wesseling, Pieter
Publicado: (2022)

INSP-16. Focused ultrasound-mediated blood-brain barrier disruption for the treatment of pediatric high-grade glioma
por: van Vuurden, Dannis, et al.
Publicado: (2022)

INSP-05. Development of fast cortical rhythms in health and mental disease
por: Hanganu-Opatz, Ileana
Publicado: (2022)

Functional neuroimaging: the adaptive mechanisms in migraine
por: Tedeschi, Gioacchino, et al.
Publicado: (2015)

Neural plasticity and migraine
por: Coppola, Gianluca
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h1q1euuadl8er0mupl89jpug1j